ARCHIVES

NCI Human Tissue Network Resources Available For Research

This article is from The Cancer Letter archive.

Vol. 23 No. 03 | January 24, 1997

Download PDF Visit The Full Archive

Related Articles

Growth Of The Cost of Drugs Slows to 5.4 Percent per Year; 21 Therapies Launched in 2 Years

May 9, 2014

New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial

May 30, 2014

Cancer Letter Closes Out 1983, 10th Year

December 16, 1983

FDA Declares Taxol Orphan Drug For KS; Can IVAX Break Bristol’s Exclusivity?

August 15, 1997

NCI Approved Clinical Trials

May 28, 2010

Protocols Approved During The Month of September 2001

October 26, 2001